tbuckley/cabot-search huggingface dataset:
PWE-129 Survey of Potential Blood Donors with Stable Haemochromatosis
Authors: C Wong, M Camarata, J Stenner
Journal: Gut (2016)

<h3>Introduction</h3> Hereditary haemochromatosis (HH) is a genetic disease characterised by excessive intestinal absorption of dietary iron, with a prevalence in the UK of 1 in 200. This results in a pathological accumulation of iron in organs such as the liver. Lifelong regular venesection remains the mainstay of treatment to achieve ferritin levels of &lt;50μg/L. European Association for the Study of the Liver (EASL) guidelines state that blood from stable, uncomplicated HH patients who fulfil blood donor selection criteria should be made available to blood transfusion services. Statistics from the NHS blood and transplant service (NHSBT) show a 40% drop in new blood donors this decade. Given the increasing donor shortage, utilising otherwise discarded blood from eligible HH patients would aid in easing the national crisis. This survey aims to understand the barriers to eligible HH patients becoming blood donors. <h3>Methods</h3> We identified all HH patients receiving regular venesections between May 2014-May 2015, at the nurse-led unit within Surrey and Sussex Healthcare NHS Trust. A random sample of patients potentially suitable for referral to NHSBT based on age (17–65 years) and stable ferritin (&lt;200μg/L for 6 months) were interviewed by telephone. <h3>Results</h3> 112 HH patients were venesected regularly (&gt;2 occasions) over this period. 40% (45/112) had ferritin levels consistently &lt;200μg/L. Of these stable patients, 75% (34/45) were identified as potential blood donors based on age criteria. 16 out of 34 (47%) patients were interviewed. There were no blood donors within the sampled cohort. Only 50% (8/16) were aware they could potentially make regular blood donations (subject to donor selection criteria) as part of their venesection programme. Within this group, a specialist was responsible for informing the patient in only 62.5% (5/8) of cases. Of note, 37.5% (6/16) of patients interviewed had less than yearly specialist clinic follow up. Encouragingly, 81% (13/16) of patients were interested in becoming blood donors. <h3>Conclusion</h3> This survey identified a substantial proportion (30% = 34/112) of HH patients within our cohort who are missed potential blood donors. This is due to a lack of patient education and awareness of referral procedures on the part of the medical team. The specialist team should facilitate blood donations by referring eligible patients to the NHSBT, providing a clear venesection plan and monitoring schedule. Regular specialist follow up is key to ensuring compliance with treatment and achieving therapeutic targets. We have introduced local protocols for HH patients and increased educational resources for both patients and clinicians. Such measures applied nationally will optimise HH management and increase the utilisation of an otherwise wasted resource. <h3>Disclosure of Interest</h3> None Declared
AHOD00P1, a Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease.
Authors: Tanya Trippett, Pedro De Alarcon, Wendy London, Richard Sposto, Allen Chen, Sharon Gardner, Cindy Schwartz
Journal: Blood (2004)
P210 Community Acquired Pneumonia- Severity and Mortality: Abstract P210 Table 1
Authors: K Tariq, P McDermott, S Sunny, H Burhan, J Hadcroft
Journal: Thorax (2015)

<h3>Background</h3> Community acquired pneumonia (CAP) is a common cause of hospital admissions and carries a high mortality rate. Risk stratification through clinical assessment, underlying chronic lung disease, SIRS and CURB65 helps identify patients at moderate to high risk of mortality. Despite prompt and appropriate management, a significant number of patients (18.3%) die in hospital (BTS Adult CAP audit 2009/10). <h3>Aims and objectives</h3> We wished to determine our hospital’s CAP mortality rate and ascertain the proportion of patients with a high likelihood of death, as predicted by high CURB-65 scores, markers of severe infection (SIRS criteria) and underlying chronic respiratory disease. <h3>Methods</h3> Case notes of all patients admitted with CAP over a 3 month period were requested and 175 were obtained. Information was gathered on the presence of underlying chronic lung conditions, CAP severity/mortality markers (SIRS and CURB65 scores) and mortality. <h3>Results</h3> At least one underlying chronic pulmonary condition was found in 45.1% (n = 79), the commonest being COPD (n = 56). CURB65 score was 0 to 1 in 39.4% (low risk), 2 in 27.4% (moderate risk), 3–5 in 17.2% (high risk) and not done in 16% (n = 28). SIRS criteria were met in just under half of the cases (48.5% n = 85). An in-patient mortality review during this study period showed that 8% (n = 14) CAP patients died in hospital within 30 days. An association of these patients with background lung condition, CURB65 and SIRS is shown in Table 1. <h3>Conclusion</h3> We showed an improvement in mortality figures compared with the BTS National CAP adult audit 5 years ago (8% vs 18.3%). A significant number of these patients have an underlying chronic lung disease which predisposed them to developing CAP. The highest mortality was seen in patients with a high CURB65 score with SIRS response.
PTU-107 The Use of the Malnutrition Universal Screening Tool in a Specialist Hospital: An Audit
Authors: SS Malik, SM Gabe
Journal: Gut (2016)

<h3>Introduction</h3> The British Association of Parenteral and Enteral Nutrition’s (BAPEN) nutritional screening week in 2011 found that 25–34% of patients admitted to hospital were at risk of malnutrition. It results in longer admissions and greater morbidity and mortality, costing in excess of £13 billion per annum. Malnutrition poses a substantial burden both medically and financially, which has resulted in the National Institute of Clinical Excellence (NICE), formulating quality statements and guidelines, which state that all patients must be screened for the risk of malnutrition using a validated screening tool. The Malnutrition Universal Screen Tool (MUST) is a well recognised and utilised screening tool, which is also recommended by NICE and BAPEN. The aim of this audit is to investigate whether inpatients at a specialist hospital are being screened for malnutrition using the validated MUST and whether this is being utilised correctly. <h3>Methods</h3> Inpatients at a spcialist hospital were identified. All patients’ notes were obtained and searched for the presence of the MUST and a MUST score. Patients’ age and time taken from admission for a MUST score to be calculated were recorded. The MUST score was also independently calculated and checked against documented scores. <h3>Results</h3> 61 inpatients were identified (31 males and 30 females). The MUST was present for 59 (96.7%) patients and a MUST score was documented for 51 (83.6%) of these patients. The MUST score was calculated after a mean of 2 days. 23 (37.7%) patients had an incorrect MUST score. A total of 33 (54.1%) patients either had no MUST present, no MUST score documented or an incorrect MUST score. 24 (39.3%) of these patients were subsequently allocated the incorrect risk category. <h3>Conclusion</h3> Malnutrition poses a major medical and financial burden. Whilst the MUST is a well-validated tool and is being completed in the majority of patients, it is not being utilised correctly and a significant number of inpatients at risk of malnutrition are not receiving the correct management. It is evident that unintentional weight loss of patients is not being elicited and in some cases alternative routes to calculating a patients BMI, if weight and height are unobtainable, have not been explored. Healthcare professionals need to be educated on the importance of unintentional weight loss and a patients’ BMI and these must be elicited. Trust guidance on calculating the MUST score must be reviewed by all nurses and doctors. The availability of the MUST application for mobile devices, designed to aid calculating the MUST score, should be promoted. <h3>Disclosure of Interest</h3> None Declared
AB0029 Relationship SCD36 Levels and Disease Activity in Patients with Rheumatoid Arthritis
Authors: A.A. Saldaña Millan, J.D.J.E. Gόmez Bañuelos, P.M. Madrigal Ruíz, E. Chavarría Άvila, B.T. Martín Márquez, R.E. Navarro Hernández, M. Vázquez-Del Mercado
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The main cause of death in RA patients is cardiovascular disease [1]. CD36 is a scavenger receptor has been postulated as a molecule involved in the atherogenic process [2,3]. A soluble fraction, sCD36 has been reported and has been proposed as a marker of atherosclerosis and other metabolic diseases [4,5], however, little is known of the pathways involved in these processes in RA. <h3>Objectives</h3> The objective of this study was to evaluate the levels of sCD36 and examine the association between clinical characteristics, disease activity and inflammatory markers in patients with RA. <h3>Methods</h3> The study groups were composed of 59 patients with RA (ACR/EULAR 2010) vs. 79 controls. sCD36, PCR, FR, Anti-CCP, insulin, TC, TG, HDL-C, VLDL-C, LDL-c were measured by ELISA. Index Disease Activity 28 (DAS-28) C-reactive protein (CRP) was calculated. VSG by Wintrobe method. cIMT using a Class B ultrasonography. Data were analyzed using descriptive statistics, Student t test, chi-square and ANOVA, as appropriate, with SPSS V.23 software. <h3>Results</h3> We found high levels of sCD36 in the control group (1861.10 ±6491.42±29.87 vs. 76.71, P&lt;0.01) as well as ESR (21.26±12.79 vs. 13.29±8.85, P&lt;0.01), CRP (8.97±7.32 vs. 7.27±4.11, P&lt;0.01), and VLDL-c (33.36±17.26 vs. 52.21±21.70, P&lt;0.01). sCD36 was positively correlated with the levels of DAS28pCr, PCR, FR, TG, insulin and IMT; negatively with HDL-c. Finally, we note a proportional direct relationship between sCD36 levels and Index Disease Activity 28 by pCr (Fig. 1). <h3>Conclusions</h3> High levels of sCD36 were observed in serum from RA patients compared to a control group, as well as a relationship between sCD36 levels and Index Disease Activity 28 by pCr. It could be proposed to sCD36 as a marker of clinical activity of RA, however, more studies are needed to validate our findings and clarify the regulation and the role of sCD36 in RA. <h3>References</h3> Solomon, D.H., et al., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 2003. 107(9): p. 1303–7. Freeman, M.W., Scavenger receptors in atherosclerosis. Curr Opin Hematol, 1997. 4(1): p. 41–7. Silverstein, R.L., Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med, 2009. 76 Suppl 2: p. S27–30. Handberg, A., et al., Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation, 2006. 114(11): p. 1169–76. Liani, R., et al., Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med, 2012. 52(8): p. 1318–24. <h3>Disclosure of Interest</h3> None declared
Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis
Authors: Britta E. Jones, Jiajin Yang, Akhil Muthigi, Susan L. Hogan, Yichun Hu, Joshua Starmer, Candace D. Henderson, Caroline J. Poulton, Elizabeth J. Brant, William F. Pendergraft, J. Charles Jennette, Ronald J. Falk, Dominic J. Ciavatta
Journal: Journal of the American Society of Nephrology (2016)

ANCA-associated vasculitis is an autoimmune condition characterized by vascular inflammation and organ damage. Pharmacologically induced remission of this condition is complicated by relapses. Potential triggers of relapse are immunologic challenges and environmental insults, both of which associate with changes in epigenetic silencing modifications. Altered histone modifications implicated in gene silencing associate with aberrant autoantigen expression. To establish a link between DNA methylation, a model epigenetic gene silencing modification, and autoantigen gene expression and disease status in ANCA-associated vasculitis, we measured gene-specific DNA methylation of the autoantigen genes myeloperoxidase ( MPO ) and proteinase 3 ( PRTN3 ) in leukocytes of patients with ANCA-associated vasculitis observed longitudinally ( n =82) and of healthy controls ( n =32). Patients with active disease demonstrated hypomethylation of MPO and PRTN3 and increased expression of the autoantigens; in remission, DNA methylation generally increased. Longitudinal analysis revealed that patients with ANCA-associated vasculitis could be divided into two groups, on the basis of whether DNA methylation increased or decreased from active disease to remission. In patients with increased DNA methylation, MPO and PRTN3 expression correlated with DNA methylation. Kaplan–Meier estimate of relapse revealed patients with increased DNA methylation at the PRTN3 promoter had a significantly greater probability of a relapse-free period ( P &lt;0.001), independent of ANCA serotype. Patients with decreased DNA methylation at the PRTN3 promoter had a greater risk of relapse (hazard ratio, 4.55; 95% confidence interval, 2.09 to 9.91). Thus, changes in the DNA methylation status of the PRTN3 promoter may predict the likelihood of stable remission and explain autoantigen gene regulation.
Exploring the Significance of TP53, ABCB1 and GST Polymorphisms on Susceptibility and Pharmacogenetics in Argentinian Patients with Chronic Myeloid Leukemia
Authors: Natalia Weich, Cristian Ferri, Elena Beatriz Moiraghi, Raquel Maria Nelida Bengio, Isabel Amanda Giere, Carolina Pavlovsky, Irene Larripa, Ariela Freya Fundia
Journal: Blood (2015)
Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy.
Authors: Robert H. Vonderheide, Charu Aggarwal, David L Bajor, Jessica Goldenberg, Christine Loch, Jessica C Lee, Jian Yan, Matthew P Morrow, Angela DeMichele, Corey J. Langer, Peter J. O'Dwyer, David B. Weiner, Zandong Yang, Mark L. Bagarazzi
Journal: Journal of Clinical Oncology (2015)

TPS3104 Background: hTERT, the human catalytic reverse transcriptase subunit of telomerase, is highly expressed in breast, lung, and pancreatic cancers. Peptides derived from hTERT can be recognized on MHC by cytotoxic T cells and mediate tumor death. In preclinical studies, TERT DNA delivered with electroporation (EP) triggered an immune response in vivo that slowed tumor growth in HPV16-associated tumor-bearing mice. The advantages of DNA-based immunotherapy include (1) strong immunogenicity exceeding those achieved by viral vectors; (2) non infectiousness of the immunogen; (3) ability for repeated dosing; and (4) relatively low cost. EP can be used to optimally and safely deliver DNA in vivo by creating a transient electric field to enhance the cellular uptake of large molecules such as DNA. Addition of IL-12 to hTERT significantly enhanced immune responses in preclinical models. We hypothesized that generation of robust T-cell immunity by immunotherapy with hTERT + IL-12 can be clinically used to reduce the risk of relapse in high-risk cancer patients in the adjuvant setting. Methods: This hypothesis is being tested in a phase 1 clinical trial (NCT02327468) sponsored by Inovio and opened at Abramson Cancer Center of the University of Pennsylvania. INO-1400 is a plasmid encoding hTERT. INO-9012 is a dual promoter plasmid encoding human IL-12 subunits p35 and p40. INO-1400 and INO-9012 are delivered IM followed by EP with the CELLECTRA device. This is an open-label, dose escalation study in patients with lung, pancreas, or breast carcinomas at high risk of relapse. Eligible patients must have early stage ER+ or HER2+, or any stage triple negative breast cancer; or Stage IB-IIIA NSCLC; or Stage I-III pancreatic cancer. Patients will enroll ≥ 4 and ≤ 16 weeks from completion of definitive surgery and adjuvant therapy into 1 of 6 cohorts (total N = 54): dosing INO-1400 at 2 or 8 mg ± INO-9012 at 0.5 or 2 mg, with EP, once every 4 weeks for 4 total treatments. Primary Endpoints:Safety and tolerability. Secondary Endpoints:(1) Time to progression; (2) Antigen-specific T cell response by IFN-γ ELISpot and flow cytometry; (3) antigen-specific humoral responses by ELISA. Clinical trial information: NCT02327468.
Identification of Thrombospondin-1 and L-Selectin as Potential Plasma Biomarkers of Silent Cerebral Infarct In Children with Sickle Cell Disease Using a Proteomic-Based Approach
Authors: Lisa M. Williams, Zongming Fu, Pratima Dulloor, Kun Yan, John J. Strouse, William Savage, Emily Barron-Casella, Michael R. DeBaun, Jennifer E. Van Eyk, Allen Everett, James F. Casella
Journal: Blood (2010)
AB0409 Modified Homa-Ir Index in Patients with Rheumatic Diseases Receiving Glucocorticoid Therapy
Authors: G. Nurullina, F. Valeeva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> HOMA-IR index is widely used in current clinical practice for the evaluation of insulin resistance (IR). Elevation of HOMA-IR index is an indirect marker of IR progression. <h3>Objectives</h3> To evaluate the role of modified HOMA-IR index in patients with rheumatic diseases receiving glucocorticoid (GC) therapy. <h3>Methods</h3> The study included 98 patients with rheumatic diseases, including systemic lupus erythematosus (SLE) - 53 patients and systemic vasculitis (SV) – 45 patients. The first group included 52 patients receiving GC pulse-therapy (GC-PT) (prednisolone 10–15 mg/kg a day i/v, on 3 consecutive days), the second group included 46 patients receiving oral prednisolone 15–30 mg/day. The first group included 31 (59.6%) women and 21 (40.4%) men aged 18–69 years. Control group included 27 (58.7%) women and 19 (41.3%) men aged 19–63 years. All patients underwent standard clinical evaluation and an oral glucose tolerance test (OGTT): patients receiving GC-PT underwent OGTT 72 hours after the end of PT course, patients receiving oral GC – during the time of inpatient treatment. According to OGTT results patients were divided into 4 groups: no carbohydrate metabolism disturbance (CMD), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and diabetes mellitus (DM). IR calculation according to HOMA-IR index was performed according to a formula proposed by X. Li et al. (2004): Homa-IR =1,5 + fasting blood glucose (mmol/l) x fasting C-peptide level (pmol/l) /2800. <h3>Results</h3> CMD developed in 10 (33.3%) patients in SLE group receiving GC-PT, compared to 18 (81.8%) patients receiving oral GC (p=0.002). In SV patients CMD was more prevalent in those receiving oral GC compared to GC-PT (4 (19.1%) vs. 19 (79.2%) patients, respectively (p=0.035). HOMA-IR index, reflecting the degree of IR, was elevated in patients with IGT and DM at baseline, during maximal blood glucose level and after GC-PT, compared to patients without CMD and IFG (p&lt;0.05). IR was more pronounced in patients receiving oral GC and IGT and DM after OGTT (p&lt;0.05), which demonstrates that a more pronounced IR during GC therapy predisposes to the development of more pronounced CMD. <h3>Conclusions</h3> GC therapy results in the development of IGT and DM in patients with elevated IR after GC-PT or prolonged oral GC treatment. CMD is more prevalent among patients receiving prolonged oral GC therapy. <h3>Disclosure of Interest</h3> None declared
Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients
Authors: Anthony Q Pham, Megan M. O'Byrne, Prashant Kapoor, Mithun Vinod Shah, Roshini S Abraham, Ronald S. Go, Alexandra Wolanskyj, Sameer A. Parikh
Journal: Blood (2015)
A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.
Authors: Luhua Wang, Luis Fayad, Fredrick B. Hagemeister, Sattva Neelapu, Felipe Samaniego, Peter McLaughlin, Barry Samuels, Qing Yi, Barbara Pro, Michelle Fanale, Jatin Shah, Anas Younes, Neda Bell, Robert Knight, Jerome B. Zeldis, Fernando Cabanillas, Larry Kwak, Jorge Romaguera
Journal: Blood (2009)
Response to Adjuvanted Monovalent Influenza A (H1N1)v Vaccine In Allogeneic Hematopoietic Stem Cell Transplant Recipients
Authors: Nathalie Dhedin, Jacques-Olivier Bay, Patricia Ribaud, Mathieu Coudert, Marie T Rubio, Philippe Agape, Anne Thiebaut, Alice Garnier, Aurelie Faugeras, Nicole Lecorre, Madalina Uzunov, Nabila Kerbi-Hamimed, Gérard Socié, Noel Milpied, Brigitte Autran, Anne Krivine
Journal: Blood (2010)
Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys
Authors: Alexandra Schiviz, Gerald Hoebarth, Martin Wolfsegger, Paolo Rossato, Alfred Weber, Herbert Gritsch, Hanspeter Rottensteiner, Peter L. Turecek, Friedrich Scheiflinger, Werner Hoellriegl, Marietta Putz
Journal: Blood (2015)
Using all available agents may be useful as 2nd or higher line CT for pts with ARGC after the failure of S-1 based CT
Authors: Kazuma Kobayashi, Kengo Kanetaka, Akira Yoneda, Mitsuhisa Takatsuki, Fumihiko Fujita, Takuya Honda, Minoru Fukuda, Kazuto Ashizawa, Tamotsu Kuroki, Susumu Eguchi
Journal: Annals of Oncology (2015)
AB0795 Hypovitaminosis D and Calcium Intake of Adult Population in Bogota (DICAVITD)
Authors: R.A. Guzman Moreno, L.G. Piñeros, A. Teheran, J. Flechas, M. Mejia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The calcium intake on the diet below normal daily requirements is related with low levels of vitamin D. The available scientific evidence supports a key role of calcium and vitamin D in skeletal health. We analyzed this relationship in healthy colombian population and describe this association. <h3>Objectives</h3> The main objetive is to Assess the prevalence of hypovitaminosis D and the relationship with the daily calcium intake in a healthy Colombian population. Furthermore it is crucial to estimate the impact of key mineral elements such as Calcium and Vitamin D in bone health. <h3>Methods</h3> In a prospective cohort of general population we measure the prevalence of hypovitaminosis D and the calcium intake, (mg/dl) following demographic, antropomethric, biochemical characteristics and sun exposure of the population evaluated. We used a model of multiple regresion to predict the levels of vitamin D regarding the factors analysed. We excluded patients with secondary conditions that affect the absorption of calcium and vitamin D. <h3>Results</h3> We included 97 patients, average age 23 yrs, 61% women, average weight 65 kg, Height 165 cm, average BMI 22.8. The calcium intake was 393,7 mg/d, levels of vitamin D were 23.71. We identified hypovitaminosis D in 87% of the patients, 24.7% had vitamin D defficiency and 63% had insufficiency (Figure 1, Levels of Vitamin D in the population study). The concentration of Vitamin D was calculated in quadratic function, for the relationship between sex, sun exposure and habitual calcium intake. (R:&gt;90%). <h3>Conclusions</h3> We found a strong relationship between low calcium intake and hypovitaminosis D in the study group. In a healthy colombian population we saw an important low intake of calcium on the diet and high prevalence of Hypovitaminosis D. These findings have enormous impact on public health policy in our country. Effective and imperative strategies are required to prevent future complications such as Osteoporosis and secondary fractures. <h3>References</h3> Catharine-Ross A., et al. The 2011 report on dietary references intake for calcium and vitamin D from the Institute of Medicine. What clinicians need to know. JCEM 2011;96:53–58 <h3>Disclosure of Interest</h3> None declared